deltatrials
Completed PHASE3 NCT00093158

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation

Sponsor: The Medicines Company

Conditions Acute Disease Myocardial Infarction Unstable Angina
Interventions Angiomax (bivalirudin) anticoagulant
Updated 5 times since 2017 Last updated: Aug 20, 2007 Started: Aug 31, 2003 Completion: Jan 31, 2007

Listed as NCT00093158, this PHASE3 trial focuses on Acute Disease and Myocardial Infarction and remains completed. Sponsored by The Medicines Company, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The Medicines Company
Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States